Onconova Therapeutics Interest Expense 2011-2026 | ONTX

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Onconova Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
289 K	1.35 M	663 K	12 K	48 K	143 K	1.15 M	30 K	62 K	-35 K	2 K	4 K	8.61 M	19 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
8.61 M	-35 K	882 K

Quarterly Interest Expense Onconova Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
96 K	188 K	180 K	-	61 K	205 K	229 K	-	350 K	360 K	362 K	-	243 K	96 K	10 K	-	7 K	-13 K	19 K	-	-23 K	96 K	96 K	-	27 K	40 K	68 K	-	117 K	112 K	-	-	8 K	11 K	-	-	10 K	10 K	9 K	-	4 K	-18 K	-18 K	-14 K	-20 K	-19 K	1 K	1 K	1 K	2 K	127 K	41 K	8.36 M	230 K	21 K	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
8.36 M	-23 K	271 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Axcella Health AXLA	3.02 M	-	-16.42 %	$ 249 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
CASI Pharmaceuticals CASI	2.9 K	-	-	$ 35.4 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
ChemoCentryx CCXI	2.7 M	-	-	$ 3.74 B	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Chimerix CMRX	11 M	-	-	$ 756 M	USA
AbbVie ABBV	2.89 B	$ 208.7	-0.07 %	$ 369 B	USA
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	7.16 M	-	-3.03 %	$ 260 M	USA
AbCellera Biologics ABCL	-2.71 M	$ 3.52	-0.14 %	$ 1.05 B	Canada